Corporate Governance and Compliance - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[4] - The financial report is guaranteed to be true, accurate, and complete by the board of directors and management[3] - The company has not disclosed any significant risks or countermeasures in the provided documents[3] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8] - The company has not disclosed any major asset or equity sales during the reporting period[8] - The company has not implemented any stock incentive plans or employee shareholding plans during the reporting period[76] - The company ensures timely, truthful, accurate, complete, and fair information disclosure, with no instances of selective disclosure[80] - The company has committed to long-term stable shareholding and has adhered to its commitments regarding share transfer restrictions[85] - The company has actively fulfilled its taxpayer obligations, ensuring timely tax payments and compliance with tax regulations[81] - The company has not faced any administrative penalties related to environmental issues during the reporting period[79] - The company emphasizes strict compliance with various environmental protection laws and has implemented internal standards for eco-friendly production[79] - The company has not reported any overdue or unrecovered amounts from its entrusted financial management activities, totaling 14.5 million CNY in investments[59] - The company has not engaged in any derivative investments during the reporting period[60] - The company did not conduct any repurchase transactions during the reporting period[123] - The company has not disclosed any differences in voting rights arrangements[123] - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[125] Financial Performance - The reporting period covers from January 1, 2023, to June 30, 2023[16] - The company's operating revenue for the reporting period was ¥170,393,701.06, a decrease of 7.91% compared to the same period last year[23] - Net profit attributable to shareholders was ¥14,366,348.89, representing an increase of 3.86% year-on-year[23] - The net profit after deducting non-recurring gains and losses was ¥5,014,136.37, up by 28.47% compared to the previous year[23] - The cash flow from operating activities was ¥2,089,685.45, down 46.05% from the same period last year[23] - The weighted average return on net assets was 1.90%, an increase of 0.21% compared to the previous year[23] - Total operating income decreased by 7.91% to CNY 170.39 million compared to the same period last year[38] - Research and development investment increased by 33.74% to CNY 12.40 million, reflecting a commitment to innovation[38] - The gross profit margin for Sodium Acetate Ringer's Injection was 84.96%, down by 8.04% from the previous year[41] - Cash flow from operating activities decreased by 46.05% to CNY 2.09 million, primarily due to reduced cash inflow[39] - Cash flow from financing activities surged by 9,408.15% to CNY 61.17 million, mainly due to increased bank loans[39] - The company reported a significant increase in revenue for the first half of 2023, achieving a total of RMB 500 million, representing a growth of 25% year-over-year[86] - The company reported a significant increase in revenue for the first half of 2023, achieving a total of 500 million CNY, representing a 25% year-over-year growth[90] - The company reported a significant increase in revenue for the first half of 2023, achieving a total of 500 million CNY for the first half of 2023, representing a 25% year-over-year growth[91] - The company reported a total revenue of 958,088,000.00 CNY for the first half of 2023, which represents a year-on-year increase of 66.3%[156] - The net profit attributable to shareholders for the first half of 2023 was 147,341,000.00 CNY, compared to 155,452,000.00 CNY in the same period last year, indicating a decrease of 5.7%[156] Product and Market Development - The main product, Sodium Acetate Ringer's Injection, generated sales revenue of ¥122,998,900, accounting for 72.19% of total revenue[30] - The domestic market share of Sodium Acetate Ringer's Injection is close to 90% as of 2022[33] - The company has submitted registration for new products, including Compound Sodium Acetate Ringer's Injection and Tranexamic Acid Injection[34] - The online sales model generated revenue of ¥5,989,500 during the reporting period[31] - The company is focusing on developing the self-pay market for its products, which has led to a decline in sales revenue due to the time required for market promotion[54] - The company is accelerating new product development in areas such as plasma substitutes, emergency medications, pediatric medications, and psychiatric medications to diversify its revenue sources[65] - The company plans to enhance its product market expansion to mitigate risks associated with price declines due to increasing competition and healthcare cost control policies[66] - The company has initiated the registration process for several new products, including Compound Sodium Acetate Ringer's Injection and Levofloxacin Sodium Chloride Injection, which are currently in the application stage[68] - The company is actively pursuing market expansion strategies, targeting an increase in market share by 15% in the next fiscal year[86] - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors by early 2024[91] Research and Development - The company holds 46 patents, including 12 invention patents, with nearly 10 invention patents currently under application[30] - The company has established a solid sales network for its core product, enhancing brand recognition and market expansion[35] - The management team possesses extensive experience in pharmaceutical marketing and R&D, ensuring effective execution of the company's strategic goals[36] - The company is investing in new technology development, allocating 50 million yuan towards R&D initiatives[89] - The company aims to enhance its research and development capabilities to introduce innovative products in the market[157] - The company has initiated research and development for new technologies aimed at enhancing product offerings and improving operational efficiency[163] Financial Position and Assets - As of June 30, 2023, the total assets of Tibet Duori Pharmaceutical Co., Ltd. amounted to CNY 954,058,745.47, an increase from CNY 898,868,684.29 at the beginning of the year, representing a growth of approximately 6.2%[135] - The company's current assets totaled CNY 666,950,662.51 as of June 30, 2023, compared to CNY 647,426,048.56 at the start of the year, indicating an increase of about 3.9%[135] - The cash and cash equivalents increased to CNY 476,639,537.54 from CNY 425,764,874.23, reflecting a growth of approximately 11.9%[135] - The company's short-term borrowings rose significantly to CNY 162,729,024.76 from CNY 100,062,416.67, marking an increase of about 62.5%[136] - The total liabilities increased to CNY 179,408,642.98 from CNY 145,527,449.90, which is an increase of approximately 23.2%[137] - The equity attributable to the owners of the parent company rose to CNY 773,720,220.39 from CNY 751,452,486.50, showing an increase of about 2.9%[137] - The company's inventory decreased to CNY 19,304,092.66 from CNY 32,767,887.11, representing a decline of approximately 41.1%[135] - The company reported a total of CNY 82,811,970.91 in long-term equity investments, showing a slight decrease from CNY 82,915,481.16 at the beginning of the year[136] - The total liabilities at the end of the reporting period were 509,000,000.00 CNY, reflecting a slight increase from the previous year's balance[154] - The total equity attributable to shareholders at the end of the reporting period was 750 million, up from 645 million at the beginning of the period, indicating a growth of 16.2%[159] Future Outlook and Strategic Initiatives - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 25%[86] - The company plans to adjust the implementation subjects of some fundraising projects to enhance the efficiency of project execution[54] - The company plans to invest 19 million CNY in purchasing land use rights and buildings for its headquarters and R&D center in Changdu, Tibet[55] - The company aims to reduce operational costs by 10% through efficiency improvements and automation initiatives by the end of 2023[91] - The company has set a performance guidance for the next quarter, expecting a revenue growth of 15% year-over-year[163] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million yuan earmarked for potential deals[89] - The company is exploring acquisitions to enrich its product portfolio and enhance market competitiveness[65] - The company plans to prioritize cash dividends, distributing no less than 10% of the annual distributable profits when conditions are met[88] - The company will link its stock incentive plan to the execution of measures to compensate for dilution of immediate returns[88] Accounting Policies and Financial Reporting - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial status accurately[173] - The company’s accounting policies include specific measures for financial instrument impairment and revenue recognition[172] - The company measures financial assets at fair value, with changes recognized in other comprehensive income, and dividends received (excluding those that recover investment costs) are included in current profit and loss[184] - Financial liabilities measured at fair value with changes recognized in profit and loss include trading financial liabilities and derivatives, with gains or losses from these liabilities recognized in current profit and loss[185] - The company applies expected credit loss model for impairment measurement of financial instruments, considering the risk of default and the present value of cash flow shortfalls[188] - The company recognizes financial assets when it transfers almost all risks and rewards of ownership, and measures them according to relevant accounting standards[186] - The company will recognize losses for financial assets that have experienced credit impairment since initial recognition, based on the adjusted effective interest rate[188] - The company continuously remeasures expected credit losses at each balance sheet date, adjusting loss provisions accordingly[191]

西藏多瑞医药股份有限公司 监事会关于第二届监事会第五次会议相关事项的监事会意见 根据《中华人民共和国公司法》《深圳证券交易所创业板股票上 市规则》《上市公司自律监管指引第 2 号——创业板上市公司规范运 作》《西藏多瑞医药股份有限公司章程》《西藏多瑞医药股份有限公司 监事会议事规则》的相关规定，监事会全体监事在认真检查和审核了 相关文件资料的基础上，就西藏多瑞医药股份有限公司（以下简称"公 司"）第二届监事会第五次会议相关事项发表如下监事会意见： 一、《2023 年半年度报告及摘要》的监事会意见 监事会认为：公司《2023 年半年度报告》及其摘要的编制程序、 半年报内容、格式符合相关文件的规定；报告内容真实、准确、完整 地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 二、《关于 2023 年半年度募集资金存放与使用情况的专项报告的 议案》的监事会意见 监事会认为：2023 年上半年，公司严格按照相关法律、法规、 规范性文件和公司《募集资金管理制度》的相关规定存放和使用首次 公开发行股票募集资金，符合证监会、深圳证券交易所关于上市公司 募集资金存放和使用的相关规定，不存在变相改变募集资金 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2023-068 表决结果：通过。 西藏多瑞医药股份有限公司 第二届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 西藏多瑞医药股份有限公司（以下简称"公司"）第二届董事会 第五次会议通知于2023年8 月12 日以邮件、微信形式发出,并于2023 年 8 月 23 日在公司会议室以现场结合通讯表决的方式召开。会议由 董事长邓勇先生主持。应出席董事 7 人，实际出席董事 7 人。监事赵 宏伟、王堂、周佳丽及高级管理人员列席本次会议。会议的召集和召 开符合《中华人民共和国公司法》《中华人民共和国证券法》等法律、 行政法规、部门规章、规范性文件及《公司章程》规定。经与会董事 审议，形成如下决议。 二、董事会会议审议情况 （一）审议通过《2023 年半年度报告及摘要》 公司《2023 年半年度报告》及其摘要的编制程序、半年报内容、 格式符合相关文件的规定；报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意 ...

非经营性资金占用及其他关联资金往来情况汇总表 2023年1-6月 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 的关联关系 | 上市公司核算 的会计科目 | 2023年期初 占用资金余 | 2023年半年度占 用累计发生金额 | 2023年半年度占 用资金的利息 | 2023年半年度偿 还累计发生金额 | 2023年半年 度期末占用 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 额 | （不含利息） | （如有） | | 资金余额 | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 其他关联方及其附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 总 ...

西藏多瑞医药股份有限公司 （以下无正文） （本页无正文，为西藏多瑞医药股份有限公司独立董事关于公司控股 股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独 立意见签字页） 独立董事：祁 飞_________ 独立董事关于公司控股股东及其他关联方占用公司资金、公司 对外担保情况的专项说明和独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》等相 关法律法规、规范性文件和《西藏多瑞医药股份有限公司章程》的规 定，我们作为公司的独立董事，本着实事求是、认真负责的态度，基 于独立判断的立场，对公司 2023 年上半年度控股股东及其他关联方 占用公司资金和公司对外担保情况进行了认真核查后，发表如下独立 意见： 一、公司控股股东及其他关联方占用公司资金情况 截至 2023 年 6 月 30 日，公司不存在控股股东及其他关联方占用 公司资金的情况。 二、公司对外担保情况 截至 2023 年 6 月 30 日，公司及其子公司不存在对外担保情况， 不存在为控股股东及其他关联方、任何非法人单位或个人提供担保的 情形。 刘颖斐_________ 王运国_________ 2023 年 8 月 25 日 ...

西藏多瑞医药股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 (一)募集资金管理情况 为了规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者权益，本公司 按照《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上 市规则（2020年12月修订）》（深证上〔2020〕1292号）及《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》（深证上〔2022〕14号）等有关法律、法规 和规范性文件的规定，结合公司实际情况，制定了《西藏多瑞医药股份有限公司募集资金管 理制度》（以下简称《管理制度》）。根据《管理制度》，本公司对募集资金实行专户存储， 在银行设立募集资金专户，并连同保荐机构中信证券股份有限公司于2021年10月20日分别 与恒丰银行股份有限公司武汉分行、兴业银行股份有限公司武汉分行、中信银行股份有限公 司拉萨分行、中信银行股份有限公司武汉分行签订了《募集资金三方监管协议》，于2021年 10月20日与子公司湖北多瑞药业有限公司、中国民生银行股份有限公司拉萨分行签订了《募 集资金四方监管协议》，于2022年7月6日分别与子公司湖北多瑞公 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2023-070 西藏多瑞医药股份有限公司 关于会计政策变更的的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 本次会计政策变更系西藏多瑞医药股份有限公司（以下简称"公 司"）根据财政部发布的相关企业会计准则解释而进行的相应变更， 无需提交公司董事会和股东大会审议，不会对公司财务状况、经营成 果和现金流量产生重大影响。 一、会计政策变更概述 （一）变更原因 2022 年 11 月 30 日，财政部发布了《企业会计准则解释第 16 号》 (财会(2022)31 号)，其中"关于单项交易产生的资产和负债相关的 递延所得税不适用初始确认豁免的会计处理"内容自 2023 年 1 月 1 日起施行。 （二）变更日期 特此公告。 西藏多瑞医药股份有限公司 由于上述会计准则解释的公布，公司需对会计政策进行相应变更， 并按以上文件规定的起始日开始执行上述会计准则。 （三）变更前采取的会计政策 本次会计政策变更前，公司执行财政部发布的《企业会计准则-- 基本准则》和各项具体会计准则、企业会计准则应用指南 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2023-073 西藏多瑞医药股份有限公司 第二届监事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 西藏多瑞医药股份有限公司（以下简称"公司"）第二届监事会 第五次会议通知于 2023 年 8 月 12 日以邮件、微信形式发出，并于 2023 年 8 月 23 日在公司会议室以现场结合通讯表决的方式召开。本 次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席 赵宏伟先生召集并主持。会议的召集和召开符合《中华人民共和国公 司法》《中华人民共和国证券法》等法律、行政法规、部门规章、规范 性文件及《公司章程》规定。经与会监事审议，形成如下决议。 二、监事会会议审议情况 （一）审议通过《2023 年半年度报告及摘要》 经审议，监事会认为公司《2023 年半年度报告》及其摘要的编制 程序、半年报内容、格式符合相关文件的规定；报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 表决结果：同意 3 票，反对 0 ...

西藏多瑞医药股份有限公司 独立董事关于第二届董事会第五次会议 相关事项的独立意见 2023 年 8 月 25 日 公司董事会关于《2023 年半年度募集资金存放与使用情况的专 项报告》真实、准确、完整地披露了公司募集资金的存放与使用情况， 公司对募集资金的投向和进展情况均如实履行了披露义务。因此，独 立董事一致同意《2023 年半年度募集资金存放与使用情况的专项报 告》。（以下无正文） （本页无正文，为西藏多瑞医药股份有限公司独立董事关于第二届董 事会第五次会议相关事项的独立意见签字页） 独立董事：祁 飞_________ 刘颖斐_________ 王运国_________ 根据《中华人民共和国公司法》《中华人民共和国证券法》等相 关法律法规、规范性文件和《西藏多瑞医药股份有限公司章程》的规 定，我们作为公司的独立董事，本着实事求是、认真负责的态度，基 于独立判断的立场，审阅了公司第二届董事会第五次会议的全部议案， 并针对需发表意见事项发表如下独立意见： 一、关于 2023 年半年度募集资金存放与使用情况的专项报告的 独立意见 2023 年上半年，公司严格按照相关法律、法规、规范性文件和 公司《募集资金管理制 ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 | 1.基本情况 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 信息披露义务人 | | | | | | 嘉兴秋昱投资合伙企业（有限合伙）（以下简称"嘉兴秋昱"） | | | 住所 | 浙江省嘉兴市南湖区南江路 | | 号基金小镇 1 号楼 | 147 | | 1856 | 室 | | -50 | | | | | | | | | 权益变动时间 2023 | 年 8 月 9 日~11 日 | | | | | | | | 股票简称 | 多瑞医药 | 股票代码 | 301075 | | | | | | 变动类型（可多选） | 增加□ 减少√ | 一致行动人 | 有□ 无√ | | | | | | 是否为第一大股东或实际控制人 | | | 是□ 否√ | | | | | | 2.本次权益变动情况 | | | | | | | | | 股份种类 | 减持股数（万股） | | 减持比例（%） | | | | | | 股等） （A 股、B | | | | | | | | ...